Celltrion, Inc. Stock price Korea S.E.
Equities
068270
KR7068270008
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- KRW | 0.00% |
Mar. 18 | South Korean Shares Close Higher on Tech Gains; Celltrion Shares Add 1% on Zymfentra Launch in the US | MT |
Mar. 18 | Celltrion's Autoimmune Disease Treatment Hits US Markets | MT |
Sales 2023 | 2,176B 1.63B | Sales 2024 * | 3,474B 2.6B | Capitalization | 37,828B 28.3B |
---|---|---|---|---|---|
Net income 2023 | 536B 401M | Net income 2024 * | 656B 491M | EV / Sales 2023 | 12.9 x |
Net cash position 2023 * | 97.38B 72.84M | Net Debt 2024 * | 1,628B 1.22B | EV / Sales 2024 * | 11.4 x |
P/E ratio 2023 * |
37.6
x | P/E ratio 2024 * |
56.8
x | Employees | - |
Yield 2023 * |
0.2% | Yield 2024 * |
0.2% | Free-Float | 36.53% |
Managers | Title | Age | Since |
---|---|---|---|
Wu-Sung Ki
CEO | Chief Executive Officer | 62 | 07-04-23 |
Ho-Seop Lee
DFI | Director of Finance/CFO | 49 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Soon-Woo Lee
BRD | Director/Board Member | 73 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
Jae-Sik Lee
BRD | Director/Board Member | 66 | - |
1st Jan change | Capi. | |
---|---|---|
+9.72% | 46B | |
+35.14% | 39.85B | |
+4.84% | 39.76B | |
+17.47% | 27.62B | |
-22.99% | 18.8B | |
+10.88% | 13.3B | |
+27.53% | 12.2B | |
-6.84% | 11.4B | |
+6.40% | 11.1B |
- Stock
- Equities
- Stock Celltrion, Inc.
- Stock Celltrion, Inc. - Korea S.E.